Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Public ClinicalTrials.gov record NCT06799247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)
Study identification
- NCT ID
- NCT06799247
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- Decartes-08 Biological
- Placebo Drug Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2025
- Primary completion
- Nov 29, 2026
- Completion
- Sep 29, 2027
- Last update posted
- Mar 23, 2026
2025 – 2027
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| A40 | Tucson | Arizona | 85718 | Recruiting |
| A13 | Carlsbad | California | 92011 | Recruiting |
| A46 | Los Angeles | California | 90095 | Recruiting |
| A14 | Orange | California | 92868 | Recruiting |
| A21 | Aurora | Colorado | 80045 | Recruiting |
| A50 | Washington D.C. | District of Columbia | 20007 | Recruiting |
| A48 | Maitland | Florida | 32751 | Recruiting |
| A10 | Tampa | Florida | 33612 | Recruiting |
| A53 | O'Fallon | Illinois | 62269 | Recruiting |
| A20 | Fairway | Kansas | 66205 | Recruiting |
| A16 | Lexington | Kentucky | 40536 | Recruiting |
| A38 | Boston | Massachusetts | 02111 | Recruiting |
| A12 | Amherst | New York | 14226 | Recruiting |
| A52 | New York | New York | 10027 | Recruiting |
| A47 | New York | New York | 10065 | Recruiting |
| A22 | Chapel Hill | North Carolina | 27599 | Recruiting |
| A39 | Charlotte | North Carolina | 28204 | Recruiting |
| A15 | Portland | Oregon | 97239 | Recruiting |
| A11 | Philadelphia | Pennsylvania | 19104 | Recruiting |
| A49 | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| A43 | Houston | Texas | 77030 | Recruiting |
| A41 | Seattle | Washington | 98195 | Recruiting |
| A54 | Milwaukee | Wisconsin | 53215 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06799247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06799247 live on ClinicalTrials.gov.